Enhanced antitumor activity of doxorubicin in breast cancer through the use of poly(butylcyanoacrylate) nanoparticles
Open Access
- 1 February 2015
- journal article
- research article
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. 10, 1291-1306
Abstract
The use of doxorubicin (DOX), one of the most effective antitumor molecules in the treatment of metastatic breast cancer, is limited by its low tumor selectivity and its severe side effects. Colloidal carriers based on biodegradable poly(butylcyanoacrylate) nanoparticles (PBCA NPs) may enhance DOX antitumor activity against breast cancer cells, thus allowing a reduction of the effective dose required for antitumor activity and consequently the level of associated toxicity. DOX loading onto PBCA NPs was investigated in this work via both drug entrapment and surface adsorption. Cytotoxicity assays with DOX-loaded NPs were performed in vitro using breast tumor cell lines (MCF-7 human and E0771 mouse cancer cells), and in vivo evaluating antitumor activity in immunocompetent C57BL/6 mice. The entrapment method yielded greater drug loading values and a controlled drug release profile. Neither in vitro nor in vivo cytotoxicity was observed for blank NPs. The 50% inhibitory concentration (IC50) of DOX-loaded PBCA NPs was significantly lower for MCF-7 and E0771 cancer cells (4 and 15 times, respectively) compared with free DOX. Furthermore, DOX-loaded PBCA NPs produced a tumor growth inhibition that was 40% greater than that observed with free DOX, thus reducing DOX toxicity during treatment. These results suggest that DOX-loaded PBCA NPs have great potential for improving the efficacy of DOX therapy against advanced breast cancers.Keywords
This publication has 56 references indexed in Scilit:
- Comparative Cardiac Toxicity of Anthracyclines In Vitro and In Vivo in the MousePLOS ONE, 2013
- Nanocarriers Enhance Doxorubicin Uptake in Drug-Resistant Ovarian Cancer CellsCancer Research, 2012
- Cytotoxicity and ion release of alloy nanoparticlesJournal of Nanoparticle Research, 2012
- Treatment of glioblastoma with poly(isohexyl cyanoacrylate) nanoparticlesInternational Journal of Pharmaceutics, 2011
- Protein Nanocapsules Containing Doxorubicin as a pH‐Responsive Delivery SystemSmall, 2011
- Drug Resistance in Breast Cancer Cells: Biophysical Characterization of and Doxorubicin Interactions with Membrane LipidsMolecular Pharmaceutics, 2010
- Endocytosis of nanomedicinesJournal of Controlled Release, 2010
- The pH-dependent association with cancer cells of tunable functionalized lipid vesicles with encapsulated doxorubicin for high cell-kill selectivityBiomaterials, 2010
- Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivoJournal of Hepatology, 2005
- Enhanced cytotoxicity of doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres against multidrug-resistant tumour cells in cultureEuropean Journal of Cancer, 1994